Abstract:Background: Metformin is a first-line drug for treating type 2 diabetes and has gained considerable interest as a potential anticancer agent. Increasing evidence suggests that metformin antagonizes diabetes and tumors through disrupting metabolic homeostasis and altering energy state. However, whether AMP activated protein kinase (AMPK) contributes to such effects of metformin remains controversial. Methods: We performed integrative metabolomics analyses to systematically examine the effects of metformin on metabolic pathways in Prkaa1 wild type (WT) and knock-out (KO) mouse embryonic fibroblast (MEF) cells as well as human cells based on gas chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry (CE-MS). Results: Metformin treatment induced metabolic reprogramming and reduced the energy state of both Prkaa1 WT and KO MEF cells, as evidenced by suppressed tricarboxylic acid (TCA) cycle, elevated lactate production as well as decreased NAD+/NADH ratio. Additionally, metabolic flux analysis also showed that metformin Ampkα-independently increased metabolic flux from glucose to lactate and decreased metabolic flux from acetyl-CoA to TCA cycle as well as from pyruvate to malate. Moreover, metformin Ampkα-dependently upregulated P-Acc but Ampkα-independently inhibited the levels of P-mTor, P-S6, Lc3, Atgl and P-Erk in MEF cells. Similarly, we demonstrated that a commonly used AMPK agonist 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) and fetal bovine serum (FBS) starvation, as a common model for energy stress, both led to Ampkα-independent metabolism alterations in MEF cells. Furthermore, these effects of metformin were also confirmed in human hepatocellular carcinoma (HCC) cells as well as in MCF10A shControl and shPRKAA1 cells. Importantly, we found that metformin could obviously inhibit colony conformation of HCC cells in an Ampkα-independent manner. Conclusions: Our data highlight a comprehensive view of metabolic reprogramming mediated by metformin as well as AICAR. These observations suggest that metformin could affect cellular metabolism largely bypassing Ampkα, and may provide a new insight for its clinical usage.

The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors

The Role of Aberrant Metabolism in Cancer: Insights into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer

Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing

Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments

Research Progress on the Use of Metformin in Leukemia Treatment

Research progress of Chinese medicine intervention on metabolism reprogramming for anti ⁃ tumor

Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer

Metabolic reprogramming in cancer: Mechanisms and therapeutics

Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies

Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches

The Critical Function of Metabolic Reprogramming in Cancer Metastasis

A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential

Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia

Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models

Metabolic Reprogramming of Chemoresistant Cancer Cells and the Potential Significance of Metabolic Regulation in the Reversal of Cancer Chemoresistance